Variables | DM (n = 100) | NDM (n = 100) | p value |
---|---|---|---|
Age (years) | 62.9 ± 9.3 | 62.9 ± 9.5 | 0.988 |
Gender (male/female) | 62/38 | 62/38 | Â |
BMI (kg/m2) | 26.1 ± 4.7 | 23.3 ± 3.3 | <0.001 |
Hypertension (yes/no) | 71/29 | 59/41 | 0.075 |
Dyslipidemia (yes/no) | 72/28 | 59/41 | 0.053 |
Past CVD events (yes/no) | 21/79 | 17/83 | 0.762 |
Smoker (yes/no) | 32/68 | 20/80 | 0.053 |
eGFR (ml/min/1.73 m2) | 85.0 ± 24.9 | 76.4 ± 16.0 | 0.004 |
FPG (mg/dl) | 132.9 ± 36.7 | 94.5 ± 10.4 | <0.001 |
HbA1c (%) | 7.2 ± 1.3 | 5.3 ± 0.4 | <0.001 |
Duration of DM (years) | 10.4 ± 9.0 |  |  |
Diabetic neuropathy (yes/no) | 48/52 | Â | Â |
Diabetic nephropathy (normo-/micro-/macro-) | 78/19/3 | Â | Â |
Anti-diabetes agents | |||
 Sulfonylurea (%) | 30 |  |  |
 Metformin (%) | 35 |  |  |
 Pioglitazone (%) | 11 |  |  |
 DPP4 inhibitor (%) | 33 |  |  |
 α-glucosidase inhibitor (%) | 9 |  |  |
 GLP1 analogue (%) | 2 |  |  |
 Insulin (%) | 19 |  |  |
VFA (cm2) | 105.2 ± 47.9 | 78.3 ± 44.6 | <0.001 |
SFA (cm2) | 165.3 ± 93.1 | 129.8 ± 74.1 | 0.003 |
log (leptin) (ng/mL) | 0.81 ± 0.41 | 0.73 ± 0.41 | 0.166 |
log (sOb-R) (ng/mL) | 1.35 ± 0.13 | 1.33 ± 0.14 | 0.214 |
log (SDNN) (ms) | 2.02 ± 0.14 | 2.05 ± 0.12 | 0.184 |
log (SDANN5) (ms) | 1.97 ± 0.14 | 1.99 ± 0.13 | 0.309 |